NCT00289536View on ClinicalTrials.gov

Dose-Response Study of Recombinant Factor VIII Manufactured Protein-Free (rAHF-PFM) in Patients With Hemophilia A

PHASE4CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

February 2, 2006

Primary Completion Date

April 1, 2007

Study Completion Date

April 1, 2007

Conditions
Hemophilia A
Interventions
BIOLOGICAL

Antihemophilic factor, recombinant, manufactured protein-free

15 IU/kg rAHF-PFM

BIOLOGICAL

Antihemophilic factor, recombinant, manufactured protein-free

30 IU/kg rAHF-PFM

BIOLOGICAL

Antihemophilic factor, recombinant, manufactured protein-free

50 IU/kg rAHF-PFM

Trial Locations (8)

Unknown

Little Rock

Los Angeles

Peoria

Iowa City

New Brunswick

Cincinnati

Oklahoma City

Houston

All Listed Sponsors
lead

Baxalta now part of Shire

INDUSTRY

NCT00289536 - Dose-Response Study of Recombinant Factor VIII Manufactured Protein-Free (rAHF-PFM) in Patients With Hemophilia A | Biotech Hunter | Biotech Hunter